Systematic review of existing guidelines for NAFLD assessment

Abstract

Aim: In this systematic review, guidelines on non-alcoholic fatty liver disease (NAFLD) were evaluated, aiming at a guideline synthesis focusing on diagnosis and staging.

Methods: A systematic literature search was conducted on any relevant database or institutional website to find guidelines on NAFLD assessment intended for clinical use on humans, in English, published from January 2010 to August 2020. Included guidelines were appraised using the AGREE II Instrument; those with higher scores and intended for use in adult patients were included in a comparative analysis.

Results: Fourteen guidelines were included in the systematic review, eight of which reached an AGREE II score sufficiently high to be recommended for clinical use, of which one developed for pediatric patients only. British and North American guidelines received the highest scores. Most guidelines recommend a screening or case-finding approach in patients with metabolic risk factors who are at increased risk of steatohepatitis or fibrosis. Ultrasound is mostly recommended to confirm steatosis, while the presence of metabolic syndrome, liver function tests, fibrosis scores, and elastographic techniques may help in selecting high-risk patients to be referred to the hepatologist, who may consider liver biopsy, although referral criteria for liver biopsy are not clearly defined. Most guidelines identify the development of noninvasive tests to replace liver biopsy as a research priority.

Conclusion: Several high-quality guidelines exist for NAFLD assessment, with no complete agreement on whether to screen high-risk patients and on the tests and biomarkers suggested to stratify patients and select those to be referred to liver biopsy.

Keywords

Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis / liver fibrosis / liver biopsy / noninvasive diagnosis / hepatocellular carcinoma / type 2 diabetes mellitus

References

[1] Anstee QM,Day CP.Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.Nat Rev Gastroenterol Hepatol2013;10:330-44

[2] Chalasani N,Lavine JE.The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.Hepatology2012;55:2005-23

[3] Sunny NE,Cusi K.Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.Trends Endocrinol Metab2017;28:250-60

[4] Marchesini G,Dalle Grave R.Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice.Hepatology2016;63:2032-43

[5] Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016;64:1388-402

[6] Kleiner DE.Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.Clin Liver Dis2016;20:293-312 PMCID:PMC4829204

[7] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[8] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[9] Anstee QM,Kotsiliti E,Heikenwalder M.From NASH to HCC: current concepts and future challenges.Nat Rev Gastroenterol Hepatol2019;16:411-28

[10] Zhu JZ,Wang YM,Yu CH.Prevalence of Nonalcoholic Fatty Liver Disease and Economy.Dig Dis Sci2015;60:3194-202

[11] Issa D,Sanyal AJ.Future therapy for non-alcoholic fatty liver disease.Liver Int2018;38 Suppl 1:56-63

[12] Petroni ML,Bugianesi E.Management of non-alcoholic fatty liver disease.BMJ2021;372:m4747

[13] Moher D,Clarke M.PRISMA-P GroupPreferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.Syst Rev2015;4:1

[14] Brouwers MC,Browman GP.AGREE Next Steps ConsortiumAGREE II: advancing guideline development, reporting and evaluation in health care.CMAJ2010;182:E839-42

[15] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.Hepatology2018;67:328-57

[16] National Institute for Health and Care Excellence (UK). Non-Alcoholic Fatty Liver Disease: Assessment and Management. Available from: https://www.nice.org.uk/guidance/ng49 [Last accessed on 30 Aug 2020]

[17] Tomasiewicz K,Halota W.Recommendations of the Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD)Recommendations for the management of non-alcoholic fatty liver disease (NAFLD).Clin Exp Hepatol2018;4:153-7

[18] Aller R,Lo Iacono O.Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.Gastroenterol Hepatol2018;41:328-49

[19] Loria P,Bellentani S.NAFLD Expert Committee of the Associazione Italiana per lo studio del FegatoPractice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee.Dig Liver Dis2010;42:272-82

[20] Wong VW,Chitturi S.Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.J Gastroenterol Hepatol2018;33:70-85

[21] Fan JG,Zhuang H.National Workshop on Fatty Liver and Alcoholic Liver DiseaseChinese Society of HepatologyChinese Medical Association; Fatty Liver Disease Expert CommitteeChinese Medical Doctor AssociationGuidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).J Dig Dis2019;20:163-73

[22] Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.Clin Mol Hepatol2013;19:325-48

[23] Watanabe S,Ikejima K.Japanese Society of Gastroenterology, Japan Society of Hepatology. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.J Gastroenterol2015;50:364-77

[24] Gao X.Study Group of Liver and MetabolismChinese Society of EndocrinologyDiagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.J Diabetes2013;5:406-15

[25] Vos MB,Barlow SE.NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).J Pediatr Gastroenterol Nutr2017;64:319-34 PMCID:PMC5413933

[26] Arab JP,Zapata R.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.World J Gastroenterol2014;20:12182-201 PMCID:PMC4161803

[27] LaBrecque DR,Anania F.Review Team, World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.J Clin Gastroenterol2014;48:467-73

[28] Bedogni G,Miglioli L.The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol2006;6:33 PMCID:PMC1636651

[29] Angulo P,Marchesini G.The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology2007;45:846-54

[30] Leoni S,Napoli L,Ferri S.Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.World J Gastroenterol2018;24:3361-73 PMCID:PMC6092580

[31] Paik JM,Biswas R,Venkatesan C.Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States.Hepatol Commun2020;4:890-903 PMCID:PMC7262283

[32] Paik JM,De Avila L,Racila A.Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States.Hepatol Commun2019;3:1459-71 PMCID:PMC6824058

[33] Edenvik P,Oksanen A,Hultcrantz R.Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?.Liver Int2015;35:1862-71

[34] Besutti G,Ligabue G.Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: A systematic review.Liver Int2019;39:1521-34

[35] Srivastava A,Tanwar S.Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.J Hepatol2019;71:371-8

[36] Blond E,Cuerq C.EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?.Diabetologia2017;60:1218-22

[37] Blank V,Beer S.Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination.Sci Rep2020;10:18345 PMCID:PMC7591877

[38] Sberna AL,Rouland A.European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.Diabet Med2018;35:368-75